TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In a prospective phase II study of 69 people with multiple myeloma and painful bone lesions, ultralow-dose radiation produced a pain response in 66% of evaluable patients at four weeks and 86% at six months. Five patients had treatment-related adverse events; none were severe, and the researchers reported no adverse effect on bone marrow status. The single-arm study did not compare the approach with standard-dose radiation in a randomized trial.
A prospective phase II trial found that ultralow-dose radiation relieved pain for many patients with multiple myeloma and painful bone lesions, while researchers reported no adverse effect on bone marrow status. Among patients who completed assessments, 66% had a complete or partial pain response at four weeks, rising to 86% at six months after either one 4-Gy treatment or two 2-Gy treatments.
The study enrolled 69 patients, who were randomly assigned to receive either a single 4-Gy fraction or two 2-Gy fractions. Both schedules deliver a total of 4 Gy, substantially below the 30 Gy in 10 fractions described in the report as a usual regimen for bone pain. The trial’s primary outcome combined pain response with changes in patients’ daily oral morphine-equivalent dose.
Response rates were calculated from patients who returned questionnaires, not the full group at every time point. At four weeks, 66% of 61 respondents met the study’s pain-response criteria. The rate was 64% among 47 respondents at eight weeks and 86% among 42 respondents at six months. The two schedules had similar response rates overall, though investigator Leslie Ballas said the median pain-score decrease at six months favored the two-fraction schedule.
Five of 69 patients had treatment-related adverse events. None reached grade 3 or higher, and none led to treatment interruption or modification, according to the report. Re-irradiation was given to 12 of 63 patients, or 19%, at doses ranging from 8 to 24 Gy; the median time to retreatment was 61 days, and 69% had a pain response after it.
Preserving Marrow for Future Care
Radiation can relieve pain from myeloma-related bone disease, but treatment planning must account for bone marrow and blood counts. Patients with myeloma may receive several lines of treatment over time, including chemotherapy and, for some, a transplant or CAR T-cell therapy. The study’s findings matter because a low initial radiation dose may offer pain relief while leaving clinicians options if symptoms recur or further treatment is needed.
That potential benefit should be weighed against the trial’s limits. Pain-response results came from progressively smaller groups of questionnaire respondents, and 19% of patients who could be assessed for retreatment received another course. The study supports consideration of a lower-dose approach; it does not establish that it is preferable for every patient or lesion.
ultralow-dose radiation therapy for bone pain
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Myeloma Radiation Doses Matter
Multiple myeloma can cause painful bone lesions, and radiation is used to ease symptoms. Ballas said that prior evidence for palliative radiation in myeloma was largely retrospective and observational. Earlier prospective evidence included a randomized comparison of 30 Gy with 8 Gy, which found complete or partial pain responses in about 80% of patients, according to the source report.
The choice of dose has gained importance as myeloma treatments have improved and patients may live long enough to receive multiple therapies. Ballas cited a five-year overall survival rate of 64% and said preserving marrow matters because it supports blood counts and future treatment options. The current trial tested two low-dose schedules but, as a single-arm phase II study, did not include a standard-dose comparison group.
“Only 19% of patients needed a second course, but it is still available to them at any point during their lifetime.”
— Leslie Ballas, MD
myeloma bone lesion pain relief products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Trial Evidence
The study was a single-arm phase II trial with two dose schedules but no standard-dose control group. The source report says investigators compared results favorably with historical controls; historical comparisons cannot establish that the low-dose schedules are equivalent or superior to other regimens.
Follow-up questionnaire numbers fell from 61 at four weeks to 42 at six months, so the later response rate reflects fewer respondents than the original 69 participants. The report does not provide enough detail to determine how missing questionnaires affected the result, how durable pain relief was beyond six months, or whether outcomes differed for specific lesion locations or patient subgroups. It also does not establish which patients are most likely to need retreatment.
pain management for multiple myeloma
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Clinicians May Apply the Findings
Ballas said she believes the two schedules are ready for clinical practice if patients are counseled that the approach is risk-adapted and some may need re-irradiation. The trial report does not describe a mandated next study or a broader guideline change. Clinicians will need to weigh pain, lesion characteristics, prior treatment, marrow concerns and the possibility of retreatment when choosing a radiation plan.
Further data could clarify how long responses last, which patients benefit most, and how low-dose treatment compares with established schedules in direct trials. Until then, the reported results provide prospective evidence for 4 Gy delivered once or in two fractions, while leaving those comparative and longer-term questions open.
bone marrow preservation radiation products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What radiation schedules did the trial test?
Patients received either one 4-Gy fraction or two fractions of 2 Gy each. Both schedules delivered a total dose of 4 Gy.
How many patients reported pain relief?
Among questionnaire respondents, 66% at four weeks and 86% at six months had a complete or partial pain response. The six-month figure was based on 42 respondents, compared with 61 at four weeks.
Did the study find severe treatment-related side effects?
Five of 69 patients had treatment-related adverse events. The report says none were grade 3 or higher or required treatment interruption or modification.
Did patients ever need another radiation treatment?
Yes. 12 of 63 patients, or 19%, received re-irradiation. Their retreatment doses ranged from 8 to 24 Gy, and the reported pain-response rate afterward was 69%.
Does this trial prove low-dose radiation is better than standard treatment?
No. This was a single-arm phase II study without a randomized standard-dose comparison group. Its results suggest the low-dose schedules can relieve pain, but they do not prove superiority or equivalence to other regimens.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
